178 related articles for article (PubMed ID: 19923869)
1. A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.
Nakai Y; Isayama H; Sasaki T; Sasahira N; Ito Y; Kogure H; Togawa O; Matsubara S; Arizumi T; Yagioka H; Yashima Y; Kawakubo K; Mizuno S; Yamamoto K; Hirano K; Tsujino T; Ijichi H; Toda N; Tada M; Kawabe T; Omata M
Oncology; 2009; 77(5):300-3. PubMed ID: 19923869
[TBL] [Abstract][Full Text] [Related]
2. Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study.
Togawa A; Yoshitomi H; Ito H; Kimura F; Shimizu H; Ohtsuka M; Yoshidome H; Kato A; Sawada S; Miyazaki M
Int J Clin Oncol; 2007 Aug; 12(4):268-73. PubMed ID: 17701005
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Oh DY; Cha Y; Choi IS; Yoon SY; Choi IK; Kim JH; Oh SC; Kim CD; Kim JS; Bang YJ; Kim YH
Cancer Chemother Pharmacol; 2010 Feb; 65(3):527-36. PubMed ID: 19578850
[TBL] [Abstract][Full Text] [Related]
4. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
[TBL] [Abstract][Full Text] [Related]
5. Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan.
Chen CY; Liang SH; Su YY; Chiang NJ; Wang HC; Chiu CF; Chen LT; Bai LY
PLoS One; 2020; 15(12):e0244487. PubMed ID: 33373398
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Ueno H; Okusaka T; Ikeda M; Ishiguro Y; Morizane C; Matsubara J; Furuse J; Ishii H; Nagase M; Nakachi K
Oncology; 2005; 69(5):421-7. PubMed ID: 16319514
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
Sudo K; Yamaguchi T; Nakamura K; Denda T; Hara T; Ishihara T; Yokosuka O
Cancer Chemother Pharmacol; 2011 Feb; 67(2):249-54. PubMed ID: 20352216
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
Morizane C; Okusaka T; Ueno H; Kondo S; Ikeda M; Furuse J; Shinichi O; Nakachi K; Mitsunaga S; Kojima Y; Suzuki E; Ueno M; Yamaguchi T
Cancer Chemother Pharmacol; 2012 Apr; 69(4):957-64. PubMed ID: 22120961
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer.
Saito K; Isayama H; Sakamoto Y; Nakai Y; Ishigaki K; Tanaka M; Watadani T; Arita J; Takahara N; Mizuno S; Kogure H; Ijichi H; Tateishi K; Tada M; Hasegawa K; Fukayama M; Kokudo N; Koike K
Med Oncol; 2018 May; 35(7):100. PubMed ID: 29846849
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
Nakai Y; Isayama H; Saito K; Sasaki T; Takahara N; Hamada T; Mizuno S; Miyabayashi K; Yamamoto K; Mohri D; Kogure H; Yamamoto N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Cancer Chemother Pharmacol; 2014 Nov; 74(5):911-5. PubMed ID: 25143299
[TBL] [Abstract][Full Text] [Related]
11. [Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer].
Nakamura K; Yamaguchi T; Sudo K; Ishihara T; Saisho H
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():219-23. PubMed ID: 16898006
[TBL] [Abstract][Full Text] [Related]
12. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
Kim MK; Lee KH; Jang BI; Kim TN; Eun JR; Bae SH; Ryoo HM; Lee SA; Hyun MS
Jpn J Clin Oncol; 2009 Jan; 39(1):49-53. PubMed ID: 19060295
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
Goji T; Kimura T; Miyamoto H; Takehara M; Kagemoto K; Okada Y; Okazaki J; Takaoka Y; Miyamoto Y; Mitsui Y; Matsumoto S; Sueuchi T; Tanaka K; Fujino Y; Takaoka T; Kitamura S; Okamoto K; Kimura M; Sogabe M; Muguruma N; Okahisa T; Sato Y; Sagawa T; Fujikawa K; Sato Y; Ikushima H; Takayama T
Cancer Chemother Pharmacol; 2015 Sep; 76(3):615-20. PubMed ID: 26220846
[TBL] [Abstract][Full Text] [Related]
14. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
Watanabe A; Kida M; Miyazawa S; Iwai T; Okuwaki K; Kaneko T; Yamauchi H; Takezawa M; Imaizumi H; Koizumi W
World J Gastroenterol; 2015 May; 21(19):5979-84. PubMed ID: 26019463
[TBL] [Abstract][Full Text] [Related]
16. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival.
Kasuga A; Okano N; Naruge D; Kitamura H; Takasu A; Nagashima F; Furuse J
Cancer Chemother Pharmacol; 2015 Mar; 75(3):457-64. PubMed ID: 25547407
[TBL] [Abstract][Full Text] [Related]
19. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Okusaka T; Miyakawa H; Fujii H; Nakamori S; Satoh T; Hamamoto Y; Ito T; Maguchi H; Matsumoto S; Ueno H; Ioka T; Boku N; Egawa S; Hatori T; Furuse J; Mizumoto K; Ohkawa S; Yamaguchi T; Yamao K; Funakoshi A; Chen JS; Cheng AL; Sato A; Ohashi Y; Tanaka M;
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1053-1059. PubMed ID: 28210843
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
Saito K; Isayama H; Nakai Y; Takahara N; Ishigaki K; Takeda T; Hakuta R; Saito T; Uchino R; Kishikawa T; Hamada T; Mizuno S; Sasaki T; Kogure H; Matsubara S; Yamamoto N; Ijichi H; Tateishi K; Tada M; Koike K
Invest New Drugs; 2019 Apr; 37(2):338-344. PubMed ID: 30411217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
